TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02579499
Drug: targeted LDL-C goal statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Statin naïve patients: Patients will be received moderate intensity statin therapy (atorvastatin 20mg or rosuvastatin 10mg)~2. Patients already received statin therapy~   * Baseline LDL-C \<70mg: same intensity of statin therapy~  * Baseline LDL-C≥70mg: uptiltrated statin therapy Patients will be tiltrated statin intensity guided by follow-up LDL-C level ( Attained LDL-C \< 50mg/dL : down regulated intensity statin therapy, 50mg/dL ≤ Attained LDL-C \< 70g/dL: maintain current intensity statin therapy, Attained LDL-C ≥ 70mg/dL: up regulated intensity statin therapy)
Study: NCT04224350
Drug: TacroBell SR cap.
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Orally, once-daily in the morning~* After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3\~12ng/ml for 0 to 3months and then at 3\~8ng/ml for 3 to 6months of study treatment.
Study: NCT02213419
Drug: Endoscopic ultrasonography-guided double ethanol lavage
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A radial echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration and ethanol lavage.~The 80 percent volume of cyst fluid was aspirated, and the pure ethanol was injected into the collapsed cyst until the original shape was restored. After 3-5 minutes, the reaspiration of the injected ethanol was then performed. The pure ethanol was reinjected into the collapsed cyst, followed by reaspiration of maximal possible volume for 3-5 minutes.
Study: NCT01119599
Drug: Gamma-Secretase Inhibitor RO4929097
Normalized name: .GAMMA.-OCTALACTONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02516020
Drug: Global
Normalized name: Global Lancet 33G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embryos are cultured in single step culture from day 1 to day 5
Study: NCT02516020
Drug: Origio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast)
Study: NCT00553072
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml/kg/dose
Study: NCT00539565
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg/kg /day from post-op day 7 - day 21~1 mg/kg /day from post-op day 22 - day 30
Study: NCT00539565
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02977065
Drug: Rosuvastatin 10 mg
Normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO daily for 4weeks
Study: NCT02977065
Drug: Rosuvastatin 10 mg + CKD-519 100 mg
Normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO daily for 4weeks
Study: NCT02405403
Drug: [18F]DPA-714 PET
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]DPA-714 Positron Emission Tomography
Study: NCT02225210
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Loading dose of fentanyl:1 μg.kg-1 . Maintenance dose of fentanyl: 0.5\~1μg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
Study: NCT00670345
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients belonging to the control group will receive the same volume of saline infusions.
Study: NCT05271370
Drug: PRO 140 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro140 SC injection 350 mg
Study: NCT05271370
Drug: PRO 140 525
Approvals — FDA: no, EMA: no, PMDA: no
Description: 525 mg
Study: NCT05271370
Drug: PRO 140 700
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 mg
Study: NCT00848731
Drug: nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nitric oxide gas is delivered by facemask
Study: NCT00564889
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m\^2 days 1, 8 \& 15 of a 28 day cycle taken orally with food
Study: NCT06292052
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Received neoadjuvant chemotherapy plus immunotherapy
Study: NCT03942185
Drug: Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.
Study: NCT03942185
Drug: Oral Chinese Herbal Medicine according with syndrome differentiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Chinese Herbal Medicine according with syndrome differentiation therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.
Study: NCT03942185
Drug: Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 \~ 200ml each time for 8 weeks.
Study: NCT02436473
Drug: Toothpaste containing 250ppm F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental toothpaste containing 250ppm F
Study: NCT01683656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procedures for the manufacturing and testing of the placebo are compiled in the IMP/study drug dossier and comply with local regulatory requirements (by GMP certified manufacturer).
Study: NCT03316820
Drug: K0706
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study treatment with water after an overnight fast
Study: NCT03316820
Drug: K0706
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study treatment with water after food
Study: NCT02224690
Drug: GWP42003-P 20 mg/kg/day Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Study: NCT00141219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00732654
Drug: Milk Protein Extract Immunotherapy goal of 4mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
Study: NCT01248455
Drug: (Anti-KIR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
Study: NCT01702467
Drug: GSK2647544
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing 0.5mg to 50mg of GSK2647544.
Study: NCT01702467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules.
Study: NCT01065818
Drug: Fluoro-L-Thymidine
Normalized name: L-thymidine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4D-PET/CT imaging with an injection of Fluoro-L-Thymidine at pre-Neoadjuvant Therapy and post-3 weeks Neoadjuvant Therapy prior to surgery.
Study: NCT00379041
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03254446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo Tablet
Study: NCT00732654
Drug: Milk Protein Extract Immunotherapy goal of 7mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
Study: NCT01617083
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antibiotic used to treat infections
Study: NCT01617083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thickening compound with sugar and flavoring
Study: NCT01949038
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01949038
Drug: Sublingual placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00950274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial injection of 5 mL of physiological saline + 10% autologous serum intramyocardially during CABG surgery
Study: NCT00146562
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
Study: NCT00146562
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
Study: NCT00948259
Drug: NP031112
Approvals — FDA: no, EMA: no, PMDA: no
Description: unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
Study: NCT00948259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
Study: NCT02424734
Drug: Aminoglycoside
Normalized name: Aminoglycoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optional, will be given as per local standard of care.
Study: NCT03350373
Drug: FYU-981
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of FYU-981 under Fasted and fed conditions in the morning.
Study: NCT01587391
Drug: Placebo to BI 163538 XX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 single dose per subject as oral solution
Study: NCT02810548
Drug: Nanohydroxyapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic bone graft
Study: NCT03580668
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: B/F/TAF administered in accordance with the approved product monograph
Study: NCT04006353
Drug: ABT
Normalized name: Abtrim
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg, Intravenous infusion
Study: NCT00046254
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03981562
Drug: Vit D
Normalized name: Tri-Vit Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take an oral vitamin D supplement once a day for 6 months.
Study: NCT03981562
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take a placebo oral tablet once a day for 6 months.
Study: NCT01614431
Drug: N acetyl cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N acetyl cysteine to cystinosis patients with CKD stages 1 to 4
Study: NCT01614431
Drug: N acetyl cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N acetyl cysteine for cystinosis patients CKD stages 1 to 4
Study: NCT06402396
Drug: bDMARDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients at time of the PDQ assessment and up to 4 months thereafter being on ongoing bDMARDs treatment or on switch of bDMARD treatment.
Study: NCT00732654
Drug: Milk Powder Immunotherapy goal dose 2000 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
Study: NCT01116102
Drug: Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution
Study: NCT00760968
Drug: TAK-783 and methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TAK-783 100 mg, tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
Study: NCT00760968
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TAK-783 placebo-matching tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
Study: NCT00790751
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minutes orally prior to initiation of sexual activity
Study: NCT01762163
Drug: Qizhitongluo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01762163
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03383315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chloride 0.9%
Study: NCT04535804
Drug: Aspirin/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: By using a random, double-blind research method, 1-550 digital computers are randomly divided into two groups, with two groups of digital coding placebo and aspirin. From 12 weeks of gestation, 100 mg of placebo or low-dose aspirin was given orally (2 tablets a time, twice a day, before going to bed) to 36 weeks of gestation.
Study: NCT03070951
Drug: OBE2109
Approvals — FDA: no, EMA: no, PMDA: no
Description: OBE2109 100mg tablets for oral administration once daily
Study: NCT03070951
Drug: Placebo to match OBE2109
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match OBE2109 100mg tablets for oral administration once daily
Study: NCT00732654
Drug: Milk Powder Immunotherapy goal dose 1000mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
Study: NCT02831543
Drug: Motireb 5/100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02831543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04080726
Drug: HIP1601
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral esomeprazole
Study: NCT04080726
Drug: HGP1705
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Nexium Tab
Study: NCT04080726
Drug: HIP1601 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo
Study: NCT04080726
Drug: HGP1705 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo
Study: NCT01335451
Drug: AZD5213
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four increasing doses for young and two increasing doses for elderly subjects. Subject will receive single dose of AZD5213 oral solution (Day 1) and then start the once daily repeated doses from Day 3 to 12 for 10 days
Study: NCT01335451
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution, single dose (Day 1) and repeated dose from Day 3 to 12 for 10 days
Study: NCT02318225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
Study: NCT01747993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (1 tablet / day for 6 days)
Study: NCT01696669
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Vincristine, 2 mg/m\^2 IV bolus, day 1.~* Doxorubicin: 75 mg/m\^2 per cycle, or 25 mg/m\^2/day x 3 days, IV infusion, 1 hour (after dexrazoxane administration at the dose of 10:1).~* Dexrazoxane: administered at a dose of 10:1, before doxorubicin only in adults.~* Cyclophosphamide: 2100 mg/m\^2 IV infusion, 6 hours, with MESNA protection, days 1 and 2.~* MESNA: used with cyclophosphamide and ifosfamide. The total daily dose of MESNA is equivalent to at least 60% of the daily dose of cyclophosphamide or ifosfamide.~* G-CSF: 5 micrograms/kg/day SC. It starts 24 hours after the last dose of chemotherapy and continues until the absolute neutrophil count is ≥ 750 mm\^3/L.~* Ifosfamide: 1800 mg/m\^2/day IV infusion, 1 hour, days 1-5 of each cycle (9,000 mg/m\^2 total maximum dose).~Window phase in high-risk patients (21-days cycle):~* Gemcitabine: 1000 mg/m\^2 IV, 90 minutes on day 1 and 8.~* Docetaxel 100 mg/m\^2, 2-3 hour infusion on day 8.
Study: NCT00979134
Drug: AZD4547
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients start at a dose of 80 mg twice daily, with no washout
Study: NCT00979134
Drug: AZD4547
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose is followed by washout 5-10 days before multiple dose
Study: NCT03875495
Drug: Temferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically modified autologous HSPCs
Study: NCT02428062
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine 5-10 mcg intravenous bolus
Study: NCT02428062
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine 0.01 - 0.1 mcg/kg/min intravenous continuous infusion
Study: NCT02428062
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine 5 - 10 mcg/kg/min intravenous continuous infusion
Study: NCT04210986
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally for two consecutive days, followed by 28 days off, then 2 more consecutive days.
Study: NCT03599609
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40mg, once daily
Study: NCT01341496
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each 4 week treatment cycle
Study: NCT01341496
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each 4 week vaccine cycle.
Study: NCT00006077
Drug: NS2330
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006077
Drug: Levodopa and Domperidone
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03935321
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 intrathecal bolus injections, each of 45mg
Study: NCT00731822
Drug: GW685698/GW642444
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW685698/GW642444
Study: NCT03288038
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03898622
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: levothyroxine with a safe dose for our population with high cardiovascular risk of 0.25mcg so that the patient's weight range between 50-80kg maintains a dosage of 0.3-0.5mcg / kg / day that does not affect the thyroid axis) fasting levothyroxine (in the case of taking a drug that interacts with absorption, use of it is changed according to the specified hours, see Table 2), and adjusted according to TSH levels \> 1 and normal T4L
Study: NCT04501250
Drug: Humulin NPH
Normalized name: Humulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection at a dose of 0.4 IU/kg
Study: NCT02175121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, once daily for 28 days
Study: NCT01349907
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines (i.e., lorazepam \[up to 4 mg/day\] or an equivalent dose of short-acting benzodiazepines) and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
Study: NCT02533141
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin Ranbaxy (Basics GmbH, Leverkusen, Germany) Dosage: 40 mg per day for 4 weeks, ingested in the morning Route of administration: peroral
Study: NCT00432666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00000484
Drug: chlorothiazide
Normalized name: Chlorothiazide
DrugBank: Chlorothiazide (DB00880)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00739635
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind treatment period of 17 weeks placebo
Study: NCT03507829
Drug: Human insulin isophane, Humulin N (Eli Lilly)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human insulin isophane, Humulin N (Eli Lilly)
Study: NCT03507829
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sliding scale short acting insulin for hyperglycemia; Sulphonylurea for NODAT
Study: NCT03113162
Drug: BEAM Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-intensity BEAM for Immunoablation
Study: NCT00742911
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take a pill of disulfiram at a fixed dose of 250 mg with their evening meal. This dose of disulfiram used to treat alcoholism. We will start by administering 2 mg of copper as copper gluconate along with 250 mg disulfiram.~Patients must not consume beverages containing alcohol while taking disulfiram.
Study: NCT02985333
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 200mgmg/m(2) IV d1,3,5
Study: NCT00884286
Drug: Aplidin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aplidin® will be administered at a starting dose of 3.2 mg/m2, as a 1-hour intravenous infusion, on days 1, 8 and 15, every 28 days cycle.
Study: NCT01779921
Drug: Plasma-derived FVII conc. (pdFVII PFL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.